Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug VV119 aims to tame schizophrenia symptoms

NCT ID NCT07703956

Not yet recruiting Disease control Sponsor: Vigonvita Life Sciences Source: ClinicalTrials.gov ↗

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests an experimental drug called VV119 in adults with acute schizophrenia. Participants receive one of three doses of VV119, a placebo, or an active comparator (aripiprazole) for six weeks. The goal is to see if VV119 reduces symptoms like hallucinations and delusions better than placebo and how it compares to a standard treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called VV119
What this could lead to
If successful, VV119 could offer a new treatment option for acute schizophrenia, potentially with fewer side effects or better symptom control than current medications.
What could go wrong
This is an early phase 2 trial, so the drug may not prove effective or safe. Side effects are unknown, and results may not apply to all patients with schizophrenia.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Anding Hospital of Capital Medical University

    Beijing, Beijing Municipality, China

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.